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The association of ribosomal proteins with carcinogenesis of nasopharyngeal carcinoma (NPC) has been established in a limited
subset of ribosomal protein genes. To date, three ribosomal protein genes, eL27 (L27), eL41 (L41), and eL43 (L37a), have been found
to be differentially expressed in cell lines derived from NPC tumors. This raises the possibility of more ribosomal protein genes
that could be associated with NPC. In this study, we investigated the expression profiles of eight ribosomal protein genes, uS8 (S8),
uS4 (S9), eS31 (S27a), eL6 (L6), eL18 (L18), uL14 (L23), eL24 (L24), and eL30 (L30), in six NPC-derived cell lines (HONE-1, SUNE1,
HK1, TW01, TW04, and C666-1). Their expression levels were compared with that of a nonmalignant nasopharyngeal epithelial
cell line (NP69) using quantitative real-time PCR (RT-qPCR) assay. Of the eight genes studied, the expressions of four ribosomal
protein genes uS8 (S8), uS4 (S9), eS31 (S27a), and uL14 (L23)were found to be significantly downregulated in NPC cell lines relative
to NP69. Our findings provide novel empirical evidence of these four ribosomal protein genes as NPC-associated genetic factors
and reinforce the relevance of ribosomal proteins in the carcinogenesis of nasopharyngeal cancer.
1. Introduction
Nasopharyngeal carcinoma (NPC) is a distinct malignant
form of head and neck cancer that originates from the lateral
or posterosuperior mucosal epithelium of the pharynx. The
World Health Organization (WHO) classifies NPC as three
major histopathologic types: Type I, keratinizing squamous
cell carcinoma; Type IIa, nonkeratinizing differentiated cell
carcinoma; and Type IIb, nonkeratinizing undifferentiated
carcinoma. Type IIb is the most common and contributes to
60% and 95% of NPC cases in North America and Southern
China, respectively, and is associated with Epstein-Barr virus
(EBV) infection [1]. Global incidence shows a pattern associ-
atedwith geographical location, where the highest prevalence
is among the Chinese population in Southeast Asia and
SouthernChina [2]. Although the involvement of genetic fac-
tors in NPC carcinogenesis is widely known, themechanisms
of their influence and/or action in the disease are not fully
understood. This could be largely due to the fact that the full
range of NPC-associated genes is still unclear. Among some
of these are the ribosomal protein (RP) genes.
The products of RP genes canonically function as major
components of ribosomes during protein biosynthesis. How-
ever, in 1996, Wool [3] listed more than 30 potential extrari-
bosomal functions of RPs that include apoptosis, DNA repair,
RNA processing, and transcription regulation. Sequence
mutation and differential expression of several ribosomal
protein genes have been reported in many human congenital
disorders and carcinomas. For instance, more than 200
distinct mutations in nine RP genes, namely, eS19 (S19), eS24
(S24), eS17 (S17), eS7 (S7), eS10 (S10), eS26 (S26), uL18 (L5),
uL5 (L11), and eL33 (L35a), were identified in a majority
of Diamond-Blackfan Anemia (DBA) cases [4–10]. Genetic
lesions in eL22 (L22) that include heterozygous deletion and
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nucleotide mutation have been found in T-cell acute lym-
phoblastic leukemia and colorectal cancer, respectively [11,
12]. Besides structural aberrancies, alteration in the expres-
sion pattern of RP genes has been found inmany types of can-
cer. These include the dysregulated expressions of uS3 (S3),
eS19, and eS31 in colorectal cancer [13–15]; eL8 (L7a), eL19
(L19), eS27 (S27), and eL37 (L37) in prostate cancer [16–19];
eS27 in cells of breast tumor and gastric carcinoma; and eL5
and eL14 in ovarian cancer [20–22]. Since 2014, a new naming
system for RP genes has been introduced to unambiguously
identify each RP gene across broad taxonomic range [23].
We adhere to this new system in this paper but have also
included the old names (in parentheses) at firstmention of the
genes.
Association of RP genes with NPC was initially reported
for eS26 and eS27.These twoRP genes were downregulated in
tumors of NPC relative to normal controls [24]. Three other
genes (eL27, eL41, and eL43) were later proven to be NPC-
associated RP factors in cell lines derived from NPC tissues
[25, 26]. However, the hypothesis of eS26 and eS27 as NPC-
associated RP genes was subsequently refuted [27]. Another
RP gene, eL32 (L32), was also found to be not involved with
NPC tumorigenesis [27]. This means that only a limited
subset of RP genes are associated with NPC.The complete list
of genes that belong to this subset is yet to be resolved. Here,
we provide evidence of four more RP genes that are relevant
to the context of NPC tumorigenesis. They are identified on
the basis of significant differential expression pattern between
NPC and nonmalignant nasopharyngeal epithelial cell lines.
2. Materials and Methods
2.1. Cell Lines and Cell Culture. Six NPC-derived cell lines
(HONE-1 [28], SUNE-1 [29], HK1 [30], TW01 [31], TW04
[31], and C666-1 [32]) and an immortalized nonmalignant
nasopharyngeal epithelial cell line (NP69 [33]) were used in
this study. Many of these were originally sourced from the
University of Hong Kong (laboratory of Professor George S.
W. Tsao) with permission for use granted by the provider.
The NPC cell lines were cultured in RPMI-1640 (Gibco, Life
Technologies, USA) containing 10% (v/v) fetal bovine serum,
2mM L-glutamine, and 100U/mL penicillin-streptomycin
(Gibco, USA). The EBV-positive cell line, C666-1, was cul-
tured on fibronectin-coated (Sigma, USA) cell culture flask
containing prewarmed (37∘C) RPMI-1640 medium. The
NP69 cells were cultured in defined keratinocyte-serum-free
medium (Invitrogen, USA) supplemented with 0.2 ng/mL
growth factors, 5% heat-inactivated FBS, and 100U/mL
penicillin-streptomycin. All cells were maintained at 37∘C in
a humidified environment containing 5% CO2. Cells were
harvested at a growth confluency of 70–80%.
2.2. Total RNAExtraction andQuantitative Reverse Transcrip-
tion-PCR (qRT-PCR). Total cellular RNAwas extracted from
the cell cultures using TRizol Reagent (Invitrogen, USA)
according to the manufacturer’s protocol. The extracted
RNAs were DNase-treated with RQ1 RNase-Free DNase
(Promega, USA). First strand cDNA was prepared using
Moloney Murine Leukemia Virus Reverse Transcriptase (M-
MLVRT; Promega, USA). Real-time PCR (or qPCR)was per-
formed using Rotor-Gene SYBR Green PCR Kit (Qiagen,
USA) and QuantiNova SYBR Green PCR Kit (Qiagen, USA)
on a Rotor-Gene 6000 Rotary Analyzer (Qiagen, USA) and
analyzed using Rotor-Gene 6000 software Version 2.3.3 (Qia-
gen, USA). For each assay, a total of 8 ng cDNA was added to
a final reaction volume of 25 𝜇L containing 1x Rotor-Gene
SYBR Green PCR master mix or QuantiNova SYBR Green
PCR master mix and 1 𝜇M of each forward and reverse
primer. Table 1 lists the details of the PCR primers used for
this study. Quantitative gene amplifications were performed
using the following thermocycling conditions: initial denatu-
ration for 5minutes at 95∘C, 40 cycles of denaturation at 95∘C
for 5 seconds, and annealing and extension at 60∘C for 20 sec-
onds. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH)
genes was used as endogenous control (or reference gene).
Nontemplate reactionwas used as negative control. Biological
triplicate tests were done for all analysis.
The selection of the threshold intensity was set at a fixed
intensity on the log-linear phase of the amplification curve
for all the samples tested. Validation experiments, which
included the generation of standard curves using a series of
diluted cDNA samples, were carried out to ensure primer
efficiency as well as target and reference gene amplification
compatibility. Melt curve analysis and conventional agarose
gel analysis were adopted alongside to verify the presence
of a single amplicon. An interassay calibration scheme was
adopted to minimize loading variation and to detect possible
contamination with the inclusion of duplicate reactions and
“no-template” control (NTC), respectively, in each qPCR
assay. All samples were normalized toGAPDH as the endoge-
nous control. Relative fold differences were calculated by the
ΔΔCT method [34].
2.3. Validation of PCR Efficiency. Primer efficiency was val-
idated by generating a duplicate fivefold serial dilution over
five-log magnitude. A calibration curve for each gene was
plotted with average quantification cycle (𝐶𝑞) values against
log input amount (4, 0.8, 0.16, 0.032, and 0.0064 ng/𝜇l). PCR
amplification efficiency was determined from the slope of the
log-linear portion of the calibration curve as follows:
Amplification efficiency = [10−1/slope] − 1. (1)
Valid ΔΔCT calculation requires the PCR amplification effi-
ciencies of the target and reference genes to be acceptably
comparable. This was determined by evaluating the relative
efficiencies of the target and reference amplification from
the individually generated standard curves using the sample
and log dilution. The Δ𝐶𝑞 values (CT target − CT reference)
were plotted against log input amount of five-template DNA
dilution (4, 0.8, 0.16, 0.032, and 0.0064 ng/𝜇l). The slope of
the resulting semi-log regression line (slope ofΔ𝐶𝑞 versus log
of input amount) was used to determine the compatibility of
the two PCR efficiencies, with the slope value (𝑚) less than 0.1
taken as ideal. In this study, primer efficiency of the respective
genes in an NPC cell line (HK1) was validated against the
reference gene, GAPDH. Quality assessment tests indicated
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Table 1: Target genes and the corresponding primer sequences, product size, and correlation coefficient of efficiency curve. F and R represent
the forward and reverse primer, respectively.
Gene name GenBank accession number Primer sequence (5󸀠-3󸀠) Expected product size (bp)
GAPDH NM 002046.5 F: CTGGGCTACACTGAGCACC 101
R: AAGTGGTCGTTGAGGGCAATG
uS8 NM 001012.1 F: GCTCAGAGTGTTGTACTCG 106
R: AGCACGATGCAATTCTTCAC
uS9 NM 001013.3 F: CTGAAGTTGATCGGCGAGTATG 280
R: ACTTGGCCAAGCCCAGCTTG
eS31 NM 002954.5 F: GCAGCTGGAAGATGGACGTAC 85
R: ACCACCACGAAGTCTCAAC
eL6 NM 001024662.1 F: GCACGTGAGAACACTGCGAG 139
R: GAGGACCCGAGCTCCAGTCAC
eL18 NM 000979.3 F: CTCTGTCCCTTTCCCGGATG 320
R: GTAGGGTTTGGTGTGGCTG
uL14 NM 000978.3 F: TCCAGCAGTGGTCATTCGAC 117
R: GCAGAACCTTTCATCTCGCC
eL24 NM 000986.3 F: CGAGCTGTGCAGTATTAGCG 117
R: GAAAGGAAAGCCGACTCGC
eL30 NM 000989.3 F: ATCTTAGTGGCTGCTGTTGG 280
R: TGCCACTGTACTGATGGACAC
that the efficiency curve for each of the primer sets relative
to GAPDH was Correlation Coefficient (𝑅2) greater than or
equal to 0.97 and PCR efficiency (or amplification compati-
bility) of at least 90% (within the ideal amplification range of
90–110%). Correspondingly, the validation plot ofΔCT versus
log input amount of RNA shows 𝑚 values within the range
of −3.6 and −3.1, thus ascertaining the validity of our qPCR
experiments.
2.4. Statistical Analysis. Amean fold difference value of more
than 1.0 was considered to be an overexpression while a fold
difference value of less than 1.0 was taken as an underex-
pression. The difference of means (target genes expression
in NP69 and NPC cell lines) was statistically evaluated
using unpaired Student’s 𝑡-test, and statistical significance
was taken at 𝑝 < 0.05.
3. Results
3.1. Relative Expression Level of RP Genes in Each NPC Cell
Line versus Normal Control. Fold difference of the 8 RP genes
in each of the 6NPC cell lines (HONE-1, SUNE-1, HK1,
TW01, TW04, and C666-1) relative to the normal control
(NP69) is shown in Table 2. Differential expression pattern
can be as small as 0.03-fold (uS4; TW01 versus NP69) to as
large as 131.92-fold (eL18; SUNE-1 versus NP69). uS8, uS4,
and uL14 are observed to be consistently underexpressed in
all six NPC cell lines when compared to NP69, with the
lowest expression observed in the SUNE-1 (0.07-fold), TW01
(0.03-fold), and SUNE-1 (0.17-fold) cell line, respectively.
Consistent upregulation in expressions of eL18 and eL30 is
observed in all six NPC cell lines relative to that of NP69,
with the highest fold difference in SUNE-1 (133.92-fold) for
eL18, and C666-1 (27.57-fold) for eL30. An interesting trend
is observed in the expression levels of eS31 and eL6 in which
their general expression trend inNPC cell lines is inconsistent
in HONE-1. For instance, expression of eS31 in NPC cell
lines maintains an upregulated pattern except in HONE-1. A
reversed scenario is evident for eL6 where a downregulation
trend is observed for all NPC cell lines except in HONE-1.
Among the 8 RP genes tested, underexpression is statistically
significant (𝑝 < 0.05) in all NPC cell lines relative to normal
control for uS8, uS4, and uL14. In the case of eS31, significant
downregulation is observed in all NPC cell lines except for
HONE-1. Its upregulated pattern in HONE-1 is not statisti-
cally significant.
3.2. Expression Level of Each RP Gene Collectively in NPC Cell
Lines Compared to NP69. To examine the overall differential
expression pattern of eachRP gene inNPC, themean fold dif-
ference of each gene in the sixNPCcell lineswas averaged and
compared to that of the normal (nonmalignant) nasopha-
ryngeal epithelial cell line, NP69 (Table 3, Figure 1). Under-
expression pattern is observed for eS8, uS4, eS31, uL14, and
uL24, with uS4 displaying the highest underexpression level
(−545.06-fold). However, only the downregulation pattern of
uL24 is not statistically significant (𝑝 = 0.054). Overexpres-
sion trend is observed for eL6, eL18, and eL30.The expression
of eL18 recorded the highest upregulation of 25.64-fold.
Nonetheless, these overexpression patterns are not statisti-
cally significant. All in all, significant differential expression
can only be concluded for eS8 (𝑝 = 0.000166), uS4 (𝑝 =
0.023), eS31 (𝑝 = 0.00025), and uL14 (𝑝 = 2.47e−05). These
genes show an underexpression pattern in NPC cell lines
compared to normal cell line.
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Table 2: Fold difference of the studied RP genes in NPC cell lines relative to normal control. Data in this table includes normalized mean
fold difference (2−ΔΔ𝐶𝑞 ) of respective genes in six NPC cell lines relative to normal nasopharyngeal epithelial cell line, NP69.
Gene Cell line Fold difference (2−ΔΔ𝐶𝑞 ) Std. deviation (SD) 𝑝 value
eS8
NP69 1.012746 0.011882
HONE-1 0.380311 0.273122 0.008019
SUNE-1 0.071494 0.009687 2.34𝑒−08
HK1 0.251844 0.163468 0.000649
TWO1 0.402658 0.44444 0.038129
TWO4 0.253709 0.282225 0.004816
C666-1 0.196327 0.085366 4.04E-05
uS4
NP69 1.21591 0.314452
HONE-1 0.164457 0.137157 0.003026
SUNE-1 0.203615 0.345601 0.009952
HK1 0.149012 0.225628 0.004405
TWO1 0.032517 0.028321 0.001452
TWO4 0.416219 0.29763 0.016465
C666-1 0.216689 0.22373 0.005476
eS31
NP69 1.013452 0.010872
HONE-1 2.637661 2.117031 0.127319
SUNE-1 0.182123 0.068557 1.6𝑒−05
HK1 0.560767 0.239252 0.015339
TWO1 0.415694 0.235145 0.005853
TWO4 0.246348 0.160656 0.000588
C666-1 0.322675 0.329258 0.011062
eL6
NP69 1.080437 0.043553
HONE-1 0.298751 0.235938 0.002428
SUNE-1 5.478057 5.216626 0.109026
HK1 10.04366 8.672146 0.073961
TWO1 2.92429 1.745115 0.070656
TWO4 6.398342 4.511504 0.055374
C666-1 2.365366 0.344513 0.001523
eL18
NP69 1.02048 0.005098
HONE-1 2.72834 1.206147 0.035128
SUNE-1 131.9168 149.1636 0.101579
HK1 3.345807 2.137831 0.066337
TWO1 1.467657 0.354116 0.047003
TWO4 1.900801 0.691558 0.046081
C666-1 12.5088 6.650983 0.020133
uL14
NP69 1.123026 0.152195
HONE-1 0.374748 0.294766 0.00872
SUNE-1 0.172974 0.057157 0.000268
HK1 0.305362 0.199669 0.002431
TWO1 0.189579 0.093481 0.000413
TWO4 0.308219 0.190789 0.002221
C666-1 0.177184 0.184382 0.001187
eL24
NP69 1.058277 0.07439
HONE-1 8.01882 9.602711 0.138828
SUNE-1 0.426845 0.363781 0.02108
HK1 1.807239 1.8652 0.262673
TWO1 0.504738 0.403963 0.039945
TWO4 0.573587 0.461182 0.073365
C666-1 0.191813 0.13318 0.000299
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Table 2: Continued.
Gene Cell line Fold difference (2−ΔΔ𝐶𝑞 ) Std. deviation (SD) 𝑝 value
eL30
NP69 1.072429 0.06969
HONE-1 5.27733 4.672817 0.097009
SUNE-1 2.217279 3.501794 0.300566
HK1 21.05978 31.37735 0.165887
TWO1 8.75249 10.80404 0.142807
TWO4 5.414118 7.185418 0.177129
C666-1 27.56961 43.37632 0.174837
Table 3: Relative expression of each RP gene in NPC cell lines compared to NP69. ∗Fold difference values < 1.0were converted to linear-scale
with the formula linear FD = (−1/FD).
Gene Cell line Mean linear FD∗ 𝑝 value Expression pattern
eS8 NP69 1.012746 0.000166 Significant underexpression
NPC −9.32115
uS4 NP69 1.21591 0.023017 Significant underexpression
NPC −545.064
eS31 NP69 1.013452 0.00025 Significant underexpression
NPC −3.34067
eL6 NP69 1.080437 0.691146 Overexpression
NPC 2.133808
eL18 NP69 1.02048 0.07951 Overexpression
NPC 25.6447
uL14 NP69 1.123026 2.47𝑒−05 Significant underexpression
NPC −7.43259
eL24 NP69 1.058277 0.053756 Underexpression
NPC −3.74191
eL30 NP69 1.072429 0.075329 Overexpression
NPC 10.82959
4. Discussion
In summary, our studies reveal the significant downregula-
tion of three 40S RP genes (eS8, uS4, and eS31) and a 60S RP
gene (uL14) inNPC cell lines. Our findings reinforce previous
reports [25, 26] on the occurrence of dysregulated expression
among a subset of ribosomal protein genes in NPC. The
differential expression pattern of eS8, uS4, eS31, and uL14 is
revealed for the first time in theNPC context and, hence, adds
to the list of possible NPC-associated RP factors.
To date, differential expression of eS8 gene and its protein
has been found in colorectal tumors/polyps [13] and colorec-
tal carcinoma [35], respectively. However, its expression is
constitutive and ubiquitous among normal and neoplastic
thyroid tissues and cell lines [36–38]. This inconsistency of
eS8’s expression characteristics across different types of can-
cer suggests its distinctive association with the type of malig-
nant tissue/cell. More studies will be required to substantiate
this. Molecularly, eS8 protein interacts with Cyclin Depen-
dent Kinase 11B (CDK11B), a key mediator of Fas ligand-
induced apoptosis [39]. It remains to be investigated whether
downregulation of eS8 affects a disrupted eS8-CDK11B inter-
action and, thus, is associated with dysregulated cellular
apoptotic pathway in NPC cells.
Differential expression of uS4 in colorectal cancer [40] is
not consistently observed for human lung squamous cell, oral
squamous cell, and liver cancer [41–43]. Similar to eS8, the
association of uS4 with cancers is likely to be type-specific.
Silencing of uS4 in glioma cells affects morphological differ-
entiation without causing senescence [44]. In human embry-
onal carcinoma NTERA2 cells, uS4 is consistently underex-
pressed during retinoic acid induced neuronal differentiation
[45]. It seems that there is relationship between the downreg-
ulation of uS4 and cellular differentiation. Our findings here
corroborate with this notion. The level (number of fold
differences) of uS4 underexpression in TW04 andC666-1 cell
lines is the lowest, followed by HONE-1 and SUNE-1, and the
highest in HK1 and TWO1 (Table 2). TWO4 and C666-1 are
undifferentiated cell lines, while HONE-1 and SUNE-1 are
from poorly differentiated squamous cell carcinoma, and
HK1 and TW01 are from differentiated squamous carcinoma.
The connection between uS4 expression and the degree of
cellular differentiation warrants more research in order to be
fully understood. At this stage, it implies that this RP can
be a possible differentiation marker amenable for accurate
histopathological analysis of NPC cells/tissues.
The eS31 is an ubiquitin C-terminal extension protein that
is overexpressed in colorectal [15], breast [46], and renal [47]
6 BioMed Research International
∗ ∗∗∗ ∗∗∗∗∗∗
eS8 uS4 eS31 eL6 eL18 uL14 eL24 eL30
NP69
NPC
−2500
−2000
−1500
−1000
−500
−200
−100
0
100
200
300
400
Av
er
ag
e f
ol
d 
ch
an
ge
Figure 1: Relative fold difference of each RP gene in NPC cell
lines versus normal control. The 𝑦- and 𝑥-axis represent average
fold difference and ribosomal protein gene types, respectively. Data
for each of the seven RP genes studied from in all the NPC
cell lines studied were pooled and compared with data from the
nonmalignant nasopharyngeal epithelial cell line, NP69. The 𝑝
values of <0.05 were considered to be statistically significant and
markedusing asterisk symbols (∗𝑝 < 0.05, ∗∗𝑝 < 0.01, ∗∗∗𝑝 < 0.001,
and ∗∗∗∗𝑝 < 0.00001). Error bars represent the upper and lower
limits of the cumulative fold difference.
cancers and leukemia [48]. It is, however, ubiquitous in
gastric and ovarian cancers [49] and downregulated in hepa-
tocellular carcinoma (HCC) tissues [50]. During ribosomal
stress, eS31 is overexpressed and the translated product
mediates activation and stabilization of p53 by binding with
MDM2 protein to inhibit MDM2-mediated p53 ubiquitina-
tion [51, 52]. Correspondingly, knockdown of eS31 mitigates
p53 activation in response to ribosomal stress [52]. This
implies a positive correlation between expressions of eS31 and
p53. However, studies have shown that p53 is overexpressed
and largely unmutated in NPC tissues and cells [53–55]. Our
findings of eS31’s underexpression in NPC cells also appear
unrelated to the trend of p53’s expression pattern in this type
of cancer. This confusion is difficult to understand without
deeper studies into the relationship between eS31 and p53
during malignant condition of NPC cells. Nevertheless, it
does suggest the notion that eS31 possibly fails to regulate p53
in the cancer situation.
The expression of uL14 is upregulated in squamous cell
carcinoma of the head and neck [56]. On the other hand, it is
underexpressed in ovarian cancer [22] andhumanpapilloma-
virus-16 E6 D25E-expressing cell lines [57]. Increase in uL14
protein inhibits HDM2-induced p53 ubiquitination [58] and
would contribute to activation and increase of p53. The
knockdown of uL14 affects actinomycin D-induced p53 acti-
vation [59]. These facts imply a positive correlation between
uL14 and p53 levels. However, in a study by Fumagalli et al.
[60], the perturbation of either 40S or 60S ribosomal bio-
genesis, which included the depletion of uL14, coincides with
the induction of p53 in A549 human lung carcinoma and
U2OS human osteosarcoma cell lines. This is consistent with
our findings and reinforces the notion of negative correlation
between uL14 expression and p53 levels in some cancer types,
in our case, NPC. The molecular explanation to this would
require further research.
Besides the cancer-type specificity of expression level of
the 4 newly identified NPC-associated RP genes, this study
has also revealed another 4 RP genes (eL6, eL18, eL24, and
eL30) that are not relevant to the context of NPC tumorigen-
esis. This underpins our suspicion of the limited selection of
RP genes that are linked to the NPC disease. The network of
their activities in the carcinogenesis of the nasopharynx will
be a potent area for future studies.
5. Conclusion
The ribosomal protein genes of eS8, uS4, eS31, and uL14 are
significantly underexpressed inNPC cell lines relative to non-
malignant nasopharyngeal epithelial cells.These genes repre-
sent the latest addition to the limited list of RP genes that have
association with cancer of the nasopharynx.
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